Colombo M P, Arioli I, Parmiani G
Int J Cancer. 1984 Dec 15;34(6):807-13. doi: 10.1002/ijc.2910340611.
The virus-induced BALB/c lymphoma YC8 is known to be lysed in vitro by syngeneic lymphoid cells immune to non-H-2 antigens of B10.D2 and DBA/2 backgrounds. This tumor is weakly immunogenic in vivo and kills 100% of syngeneic mice with 1 X 10(3) cells given either intravenously (i.v.) or intraperitoneally (i.p.). We show here that i.v.-injected YC8 cells grow preferentially in the liver, where colonies become microscopically visible after 7-10 days, and, less frequently, in the kidneys and spleen but not in the lung. Passive adoptive immunotherapy of this tumor was carried out with alloimmune BALB/c anti-B10.A, anti-pool (donors were immunized with lymphocytes from 5 different strains), anti-A and anti-DBA/2 splenic and lymph node cells. When administered i.p. 1, 3 or 5 days after tumor cells had been given i.p. and with a schedule of 5 subsequent daily inocula, anti-DBA/2 lymphocytes cured 100%, 80% and 60% of animals respectively. A weaker effect was obtained with anti-pool immune cells whereas anti-B10.A and anti-A lymphoid cells had not therapeutic effects. When given i.v., the anti-DBA/2 immune lymphocytes were able to cure both i.v. and i.p. tumor-injected mice. A significant effect was observed also when the onset of immunotherapy was delayed until 7 or 10 days after tumor injection. By depleting the BALB/c anti-DBA/2 immune cells with appropriate monoclonal antibodies and complement, it was found that Lyt 1+ 2-cells played the major role in eradicating the neoplasm. in vitro phenotypic and functional analysis showed that the immune cell population included 70% of Thy 1+, 38% of Lyt 1+ and 18-20% of Lyt 2+ cells. Immune lymphocytes were not cytotoxic in vitro to YC8 or DBA/2 targets whereas they proliferated after restimulation with DBA/2 but only weakly with YC8 cells. This shows that it is possible to cure mice bearing a disseminated lymphoma which expresses non-immunogenic antigens recognized by BALB/c anti-DBA/2 immune T lymphocytes. These immune lymphocytes had no cytotoxic activity in vitro and their major effector cell subpopulation displayed the Thy 1+, Lyt 1+ phenotype.
已知病毒诱导的BALB/c淋巴瘤YC8在体外可被对B10.D2和DBA/2背景的非H-2抗原具有免疫性的同基因淋巴细胞裂解。该肿瘤在体内免疫原性较弱,静脉注射(i.v.)或腹腔注射(i.p.)1×10³个细胞可导致100%的同基因小鼠死亡。我们在此表明,静脉注射的YC8细胞优先在肝脏中生长,7 - 10天后在显微镜下可见菌落,较少在肾脏和脾脏中生长,而不在肺中生长。用同种异体免疫的BALB/c抗B10.A、抗混合(供体用来自5种不同品系的淋巴细胞免疫)、抗A和抗DBA/2脾细胞及淋巴结细胞对该肿瘤进行被动过继免疫治疗。在肿瘤细胞腹腔注射后1、3或5天腹腔给药,并随后连续5天每天接种,抗DBA/2淋巴细胞分别治愈了100%、80%和60%的动物。抗混合免疫细胞的效果较弱,而抗B10.A和抗A淋巴细胞没有治疗效果。静脉给药时,抗DBA/2免疫淋巴细胞能够治愈静脉注射和腹腔注射肿瘤的小鼠。当免疫治疗开始延迟至肿瘤注射后7天或10天时,也观察到了显著效果。通过用适当的单克隆抗体和补体清除BALB/c抗DBA/2免疫细胞,发现Lyt 1⁺2⁻细胞在根除肿瘤中起主要作用。体外表型和功能分析表明,免疫细胞群体包括70%的Thy 1⁺、38%的Lyt 1⁺和18 - 20%的Lyt 2⁺细胞。免疫淋巴细胞在体外对YC8或DBA/2靶细胞没有细胞毒性,而在用DBA/2再次刺激后它们会增殖,但对YC8细胞的增殖较弱。这表明有可能治愈携带表达被BALB/c抗DBA/2免疫T淋巴细胞识别的非免疫原性抗原的播散性淋巴瘤的小鼠。这些免疫淋巴细胞在体外没有细胞毒性活性,其主要效应细胞亚群表现出Thy 1⁺、Lyt 1⁺表型。